Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Cancer Immunol Res. 2017 Nov 2;5(12):1141–1151. doi: 10.1158/2326-6066.CIR-17-0235

Figure 4. Cisplatin may increase tumor cell PD-L1 expression but does not reduce numbers of CD8+ T lymphocytes in vivo.

Figure 4

Tumors were harvested from a subset of MOC1 tumor-bearing mice at day 25 after tumor cell injection (n = 4 mice per group), five days after the third dose of anti–PD-L1 antibody, and four days following the second weekly dose of cisplatin. Tumor cells and intratumoral immune cells were analyzed by flow cytometry. Data from individual animals and mean are shown. * p <0.05 by two-way ANOVA and post-hoc Tukey’s multiple comparison test.